ArticleSkin health and disease2025
Observations on quality of life and disease control in patients with hereditary angioedema.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema.Clinical and translational allergy · 2026Article
- A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.Frontiers in immunology · 2026Article
- Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care.Allergologie select · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lanadelumab is administered subcutaneously at 2- to 4-week intervals for long-term prophylaxis in hereditary angioedema (HAE). The effect of longer treatment intervals on disease control or disease-related quality of life (QoL) remains elusive. Objectives: To assess whether the reduction of the burden of treatment improves QoL. Methods: The treatment outcome of 56 patients with HAE treated with lanadelumab was assessed. The last documented treatment interval was extracted from patient records; individual disease control and QoL were assessed routinely with the Angioedema Control Test (AECT) and Angioedema Quality of Life Questionnaire (AE-QoL). The evaluation was based on the duration of the injection interval, i.e. equal to or less than 28 days (L ≤ 28) or more than 28 days (L > 28). Results: In total, 56 patients were included, 23 patients with L ≤ 28 and 33 with L > 28. In the L ≤ 28 group, the mean AECT was 14 points and the AE-QoL was 24 points. In the L > 28 group, the mean AECT was 15.5 points and the AE-QoL was 11.6 points. Conclusions: We conclude that lanadelumab injection intervals can be generously individualized in many patients with HAE while fully maintaining disease control and QoL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.